GlassScriptPhysician profile
Kimberly A Simon
NPI 1053553974
$6,252.68
in general payments reported to CMS, 2019-2025
35 companies · $2,745 in 2025
The $2,745 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.71 · 2022: $336 · 2023: $1,308 · 2024: $1,850 · 2025: $2,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,903.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,375.27 | 2022-2025 | |
| Lilly USA, LLC | $646.42 | 2023-2025 | Emgality, Amyvid, Kisunla |
| Teva Pharmaceuticals USA, INC. | $478.11 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Lundbeck LLC | $453.04 | 2023-2025 | Rexulti, Vyepti |
| Novartis Pharmaceuticals Corporation | $452.04 | 2024-2025 | |
| Pfizer INC. | $449.88 | 2023-2025 | |
| Microtransponder, INC. | $265.40 | 2025 | |
| Neurocrine Biosciences, INC. | $204.64 | 2023-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $197.17 | 2023-2025 | Nayzilam, Briviact |
| Eisai INC. | $191.36 | 2023-2025 | |
| Axsome Therapeutics, INC. | $178.92 | 2025 | Symbravo |
| Medtronic, INC. | $154.49 | 2023-2025 | Interstim, Intellis Adaptivestim, Percept PC Brainsense |
| Corium, LLC | $133.19 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $127.05 | 2023-2025 | Rexulti |
| Genentech USA, INC. | $126.52 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $121.95 | 2023-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $118.44 | 2023-2025 | Crexont, Rytary |
| Biogen, INC. | $94.34 | 2021-2023 | Tysabri, Vumerity |
| Argenx US, INC. | $67.18 | 2024-2025 | Vyvgart Hytrulo |
| Impel Pharmaceuticals INC. | $56.66 | 2022-2023 | Trudhesa |
| Amgen INC. | $53.05 | 2022-2025 | Uplizna |
| Boston Scientific Corporation | $31.89 | 2025 | General - Pain Management |
| Acadia Pharmaceuticals INC | $28.92 | 2024-2025 | Nuplazid |
| Aucta Pharmaceuticals, INC. | $28.04 | 2025 | Motpoly Xr |
| Sumitomo Pharma America, INC. | $26.72 | 2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $23.64 | 2024 | Ultomiris |
| Ge Healthcare | $23.16 | 2023 | |
| Octapharma USA, INC. | $21.96 | 2023 | Panzyga |
| Janssen Biotech, INC. | $21.37 | 2025 | |
| Mallinckrodt Hospital Products INC. | $21.30 | 2023 | Acthar |
| Tanabe Pharma America, INC. | $20.57 | 2024 | |
| Supernus Pharmaceuticals, INC. | $17.50 | 2022 | |
| Sk Life Science, INC. | $14.54 | 2024 | |
| Merz Pharmaceuticals, LLC | $14.42 | 2025 | Inbrija, Xeomin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.53 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.